Lilly and Pfizer failure is not a fair arguement....it is an irrelevant one, since their approach was entirely different and targetted amyloid plaque, which Harvard in article today says is wrong approach. Our approach is the correct one and will be successful.
Unfortunately, especially when they have been tasked with speeding up alz drug approvals by the US govt
MY wife has hasimoto's disease and said she felt her mental clarity greatly improved with Anatabloc. Too bad vindictive, dirty democrapt politicians got the FDA to reclassify a natural supplement as a drug as part of their vendetta against the former Republican governor. I agree that combined with 273 is might really be something special, especially for autism. Missling could get Rock Creek for less than $5m in AVXL shares.
one thing to keep in mind is that early on the dose was not optimized, so the non-responders could be due to an insufficient dosage. the trial was adaptive, so as it continues on these people will get the optimal dose so the 52 week data should show a higher response rate
Geode is not an index fund...but you remind me that we may get added to several indexes soon, requiring funds to buy in
Between the court cast that you can sue shorts and the SEC checking their shorting of AVXL. shorting is not the easy money it used to be, even in these rigged markets.
actually would be good if true...love to see Adage, Broadfin or Baker Brother take a 20% position, even if it was a private sale of stock
shorting a vastly undervalued stock to make a couple pennies is stupid. News could blindside you at any moment
would it be fairer if I compared Cheryl's intelligence to a flatworm?
well, if you buy in a year from now you might have to pay $40 a share.....